Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIMOC1 (RAB7A-Interacting MON1-CCZ1 Complex Subunit 1) is a protein that functions as a novel regulator of mitochondrial dynamics and mitophagy in pancreatic β-cells. Highly expressed in these cells, RIMOC1 is essential for maintaining mitochondrial membrane potential, respiration, and glucose-stimulated insulin secretion (GSIS). Preclinical studies involving CRISPR-Cas9 knockout models (both in vitro and in vivo) have demonstrated that a loss of RIMOC1 leads to impaired mitophagy, reduced insulin mRNA expression, and β-cell failure. Human genomic data further supports its clinical relevance, showing a negative correlation between RIMOC1 expression and markers of diabetes progression such as HgbA1c and glucose load. Consequently, RIMOC1 is being investigated as a therapeutic target to preserve β-cell function and mass for the treatment or prevention of diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RIMOC1.